96,208 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Purchased by Dauntless Investment Group LLC

Key Points

• Dauntless Investment Group LLC has purchased 96,208 shares of Cardiff Oncology, Inc. valued at approximately $302,000, indicating growing institutional interest in the company.
• Cardiff Oncology's stock currently has a market cap of $248.14 million, with a price target of $18.00 set by HC Wainwright, reflecting positive analyst sentiment.
• The company recently reported a quarterly loss of ($0.20) earnings per share, missing analyst expectations but showing revenue slightly above predictions.

Dauntless Investment Group LLC purchased a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 96,208 shares of the company's stock, valued at approximately $302,000. Dauntless Investment Group LLC owned approximately 0.14% of Cardiff Oncology at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new stake in Cardiff Oncology in the fourth quarter worth $25,000. Ledgewood Wealth Advisors LLC purchased a new position in Cardiff Oncology during the 1st quarter valued at $35,000. Castleview Partners LLC bought a new position in shares of Cardiff Oncology during the 1st quarter worth $45,000. ProShare Advisors LLC purchased a new position in shares of Cardiff Oncology during the fourth quarter valued at $50,000. Finally, Brighton Jones LLC purchased a new position in shares of Cardiff Oncology during the first quarter valued at $52,000. Hedge funds and other institutional investors own 16.29% of the company's stock.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $3.73 on Tuesday. The business's 50-day simple moving average is $3.61 and its two-hundred day simple moving average is $3.51. The company has a market cap of $248.14 million, a PE ratio of -4.05 and a beta of 1.52. Cardiff Oncology, Inc. has a fifty-two week low of $2.01 and a fifty-two week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.09 million. Cardiff Oncology had a negative net margin of 8,308.50% and a negative return on equity of 76.45%. As a group, analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HC Wainwright boosted their price target on Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th. LADENBURG THALM/SH SH assumed coverage on Cardiff Oncology in a research report on Tuesday, July 8th. They issued a "buy" rating and a $19.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They set a "hold" rating and a $3.50 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.70.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.